Growth hormone · Long-acting GHRH analog · Research guide
Tesamorelin
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone, developed by Theratechnologies. It is FDA-approved as Egrifta for the treatment of HIV-associated lipodystrophy.
Watch
Mechanism
- GHRH receptor agonism. Similar mechanism to Sermorelin, with a longer half-life due to modifications resisting DPP-4 degradation.
Common research protocols
Dosing information below reflects published research literature. It is not medical advice and is not a treatment plan.
- FDA-approved dosing (Egrifta indication). 2 mg per day, subcutaneous injection.
Evidence at a glance
- Human data. Multiple published trials in the HIV-lipodystrophy population showing visceral adipose tissue reduction.
- Known side effects. Injection-site reactions, arthralgia, peripheral edema, hyperglycemia in a subset of users.
Reconstitution & handling
Lyophilized peptides ship as freeze-dried powder. Reconstitute with bacteriostatic water; refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How We Work page.
Primary-literature list for this guide available on request via contact.
Further reading — external professional sources
- Tesamorelin — Wikipedia
- PubMed — search "tesamorelin"
- ClinicalTrials.gov — trials for "tesamorelin"
- FDA Drugs@FDA — tesamorelin
Links open in a new tab. Private Supply is not affiliated with these sources.